Premier Biomedical, Inc., an El Poaso, Texas-based biotechnology company currently working to discover and develop medical treatments for a wide range of diseases in humans, recently announced they have established a new partnership with FBROCCO Assessoria Empresarial Ltd., a management consulting company focused on helping healthcare companies implement the right local strategies, tactics and tools required to create a sustainable competitive advantages in Brazil’s fast-growing healthcare market. The terms of the agreement stipulate that FBROCCO Assessoria Empresarial will assist Premier in locating and acquiring financing and potential joint venture partnerships in Brazil, with the main purpose of developing and marketing Premier’s medications and devices for diseases, such as fibromyalgia, MS, and cancer.
Francisco Brocco, Managing Partner of FBROCCO, said, “I am looking forward to working with Premier Biomedical to bring their innovative medical treatments to the Brazilian people as well as to all of South America. I see this as a very positive move for all concerned.”
William A. Hartman, President and CEO of Premier Biomedical, stated, “We believe Mr. Brocco and his staff have the drive and connections to find the most suitable joint venture partner for us in Brazil, to successfully bring our products quickly and safely to the entire South American market as a first step. This alliance will provide badly needed revenue in the short term to finance the further development of our extensive pipeline of new products for the market.”
Hartman will be visiting Brazil soon to hold meetings with potential partners, through the assistance of FBROCCO, and hopefully sign a new agreement. This news follows a report from June highlighting that Researchers from the University of Texas El Paso (UTEP), funded by Premier Biomedical, Inc., recently developed a single antibody that has the ability to bind three immune inhibitors, CTLA-4, PD1, and BTLA. Last May, a Provisional Patent Application was completed for this antibody family by Premier Biomedical. Dr. Georgialina Rodriguez of UTEP, a principal investigator on the project said the research team together with Premier are heavily involved in understanding more about the way these immune therapies or cancer checkpoint inhibitors function to fight and eliminate cancer, including antibodies that target molecules like CTLA4 on T-cells, a protein receptor that downregulates the immune system. Recent findings showed that targeting more than one of these proteins may have superior ability to fight cancer, making this research very encouraging.